Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Besse

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2007
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up, B Besse
Revue De Pneumologie Clinique|July 23, 2011
[What is the best sequence of treatment for patients with EGFR mutations?]B Besse, G Zalcman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?V Polo, B Besse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCC Leduc, B Besse
Revue Des Maladies Respiratoires|February 24, 2015
[Targeted therapies in non-small cell lung cancer in 2014]C Leduc, B Besse
Bulletin Du Cancer|July 28, 2010
[Internet as a tool in oncology: critical analysis]B Rousseau, B Besse,
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2014
Pharmacogenomics in NSCLC: mostly unsexy but desperately neededB Besse, M Reck
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Developments in the treatment of early NSCLC: when to use chemotherapyB Besse, T Le Chevalier
Bulletin Du Cancer|December 26, 2009
[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]D Planchard, Y Loriot, B Besse
Bulletin Du Cancer|May 13, 2009
[Targeting of the AKT-mTOR pathway in head and neck and lung cancer]S Vignot, S Haberer, B Besse
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2007
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up, B Besse
Revue De Pneumologie Clinique|July 23, 2011
[What is the best sequence of treatment for patients with EGFR mutations?]B Besse, G Zalcman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2013
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?V Polo, B Besse
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 19, 2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLCC Leduc, B Besse
Revue Des Maladies Respiratoires|February 24, 2015
[Targeted therapies in non-small cell lung cancer in 2014]C Leduc, B Besse
Bulletin Du Cancer|July 28, 2010
[Internet as a tool in oncology: critical analysis]B Rousseau, B Besse,
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2014
Pharmacogenomics in NSCLC: mostly unsexy but desperately neededB Besse, M Reck
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2012
Developments in the treatment of early NSCLC: when to use chemotherapyB Besse, T Le Chevalier
Bulletin Du Cancer|December 26, 2009
[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value]D Planchard, Y Loriot, B Besse
Bulletin Du Cancer|May 13, 2009
[Targeting of the AKT-mTOR pathway in head and neck and lung cancer]S Vignot, S Haberer, B Besse
Pageof 14